Journal Home
Search for

Volume 28, Issue 8, Pages 1139-1147 (August 2007)


View previous. 2 of 17 View next.

Aβ42 neurotoxicity in primary co-cultures: Effect of apoE isoform and Aβ conformation

Arlene M. Manellia1, Lindsey C. Bulfinchb, Patrick M. Sullivanc, Mary Jo LaDuaCorresponding Author Informationemail address

Received 21 April 2006; received in revised form 18 May 2006; accepted 19 May 2006. published online 13 July 2006.

Abstract 

Autosomal dominant mutations that increase amyloid-β(1–42) (Aβ42) cause familial Alzheimer's disease (AD), and the most common genetic risk factor for AD is the presence of the ɛ4 allele of apolipoprotein E (apoE). Previously, we characterized stable preparations of Aβ42 oligomers and fibrils and reported that oligomers induced a 10-fold greater increase in neurotoxicity than fibrils in Neuro-2A cells. To determine the effects of apoE genotype on Aβ42 oligomer- and fibril-induced neurotoxicity in vitro, we co-cultured wild type (WT) neurons with glia from WT, apoE-knockout (apoE-KO), and human apoE2-, E3-, and E4-targeted replacement (TR) mice. Dose-dependent neurotoxicity was induced by oligomeric Aβ42 with a ranking order of apoE4-TR>KO=apoE2-TR=apoE3-TR>WT. Neurotoxicity induced by staurosporine or glutamate were not affected by apoE genotype, indicating specificity for oligomeric Aβ42-induced neurotoxicity. These in vitro data demonstrate a gain of negative function for apoE4, synergistic with oligomeric Aβ42, in mediating neurotoxicity.

a Department of Medicine, Division of Geriatrics, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, United States

b Department of Anatomy and Cell Biology, University of Illinois at Chicago, 808 S. Wood St., CME 578, M/C 512, Chicago, IL 60612, United States

c Department of Medicine, Division of Neurology and Bryan ADRC, Duke University, Durham, NC 27710, United States

Corresponding Author InformationCorresponding author. Tel.: +1 312 355 4795; fax: +1 312 355 0386.

1 Permanent address: Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064-6123, United States.

PII: S0197-4580(06)00185-0

doi:10.1016/j.neurobiolaging.2006.05.024


View previous. 2 of 17 View next.